Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Prospective observational study in patients with obstructive lung disease: NOVELTY design

Helen K. Reddel, Maria Gerhardsson de Verdier, Alvar Agustí, Gary Anderson, Richard Beasley, Elisabeth H. Bel, Christer Janson, Barry Make, Richard J. Martin, Ian Pavord, David Price, Christina Keen, Asparuh Gardev, Stephen Rennard, Alecka Sveréus, Aruna T. Bansal, Lance Brannman, Niklas Karlsson, Javier Nuevo, Fredrik Nyberg, Simon S. Young, Jørgen Vestbo
ERJ Open Research 2019 5: 00036-2018; DOI: 10.1183/23120541.00036-2018
Helen K. Reddel
1Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Gerhardsson de Verdier
2Respiratory TA, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agustí
3Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Anderson
4Lung Health Research Centre, University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Beasley
5Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Beasley
Elisabeth H. Bel
6Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Janson
7Dept of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Make
8National Jewish Health and University of Colorado Denver, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Barry Make
Richard J. Martin
8National Jewish Health and University of Colorado Denver, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Pavord
9Nuffield Dept of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Price
10Observational and Pragmatic Research Institute, Singapore and Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Price
Christina Keen
11Early Clinical Development IMED Biotech Unit, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asparuh Gardev
12Global Medical Affairs, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Rennard
13Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alecka Sveréus
2Respiratory TA, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aruna T. Bansal
14Acclarogen Ltd, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lance Brannman
15US Medical Affairs, AstraZeneca, Gaithersberg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niklas Karlsson
16Patient Reported Outcomes, Medical Evidence and Observational Research, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Nuevo
17Respiratory TA, Global Medical Affairs, AstraZeneca, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fredrik Nyberg
18Medical Evidence and Observational Research, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon S. Young
19Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jørgen Vestbo
20School of Biological Sciences, University of Manchester, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    NOVELTY study design. COPD: chronic obstructive pulmonary disease; eCRF: electronic case report form; EMR: electronic medical record; HCU: healthcare utilisation; HRQoL: health-related quality of life; PRO: patient-reported outcome.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Patient demographics and characteristics to be measured in NOVELTY

    VariableCollection#
    BaselineEvery 3 monthsYearly
    Physician-reportedPatient-reportedPatient-reportedPhysician-reportedPatient-reported
    Informed consent✓
    Demographics
     Age, ethnicity, gender, socioeconomic status, income (USA only), insurance status/payee (USA only), history of respiratory interventional trials participation✓
     Occupation✓✓
    Characteristics
     Height (post-baseline for adolescents only), weight, BMI, waist circumference, heart rate, pregnancy status✓✓
    Risk factors for development of obstructive lung disease
     Smoking status and history, environmental and occupational exposure to pollutants, allergens✓✓

    BMI: body mass index; NOVELTY: a NOVEL observational longiTudinal studY. #: baseline and yearly data will be collected from healthcare professionals during clinical visits, while 3-monthly data will be collected directly from the patient via follow up by web-based platform or telephone, and in conjunction with their yearly clinical visits.

    • TABLE 2

      Disease-related variables to be measured in NOVELTY

      VariableCollection#
      BaselineEvery 3 monthsYearly
      Physician-reportedPatient-reportedPatient-reportedPhysician-reportedPatient-reported
      Asthma/COPD information
       Physician-reported diagnosis and severity✓
       Age at diagnosis, personal and family history of asthma/COPD and allergies✓
       Comorbidities✓✓
       Asthma/COPD complications, recent respiratory diseases (e.g. RTI)✓✓✓✓✓
       Exacerbations✓✓✓✓✓
       Symptom assessments: CAAT¶, RSQ✓✓✓
       Symptom assessments: ACT+, SGRQ✓✓
       mMRC dyspnoea score✓
       CAPTURE screening tool✓
       Lung function measurements (FEV1, FVC, PEF, FEF25–75%, IC, calculated FEV1/FVC ratio, calculated FEV1% predicted)§✓✓
       Bronchodilator reversibility test✓
       FeNO✓
      Biomarkers (with specific consent)ƒ
       Blood: differential white blood cell count✓✓
       Blood: serum and plasma## for biomarker, metabolomic and proteomic analysis✓✓
       Blood: DNA and RNA, for genomic and transcriptomic analysis✓
       Urine sample✓

      ACT: asthma control test; CAAT: chronic airways assessment test; CAPTURE: COPD Foundation Primary Care Tool for Undiagnosed Respiratory Disease and Exacerbation Risk; COPD: chronic obstructive pulmonary disease; FEF25–75%: forced expiratory flow at 25–75% of the forced vital capacity; FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume over 1 s; FVC: forced vital capacity; IC: inspiratory capacity; mMRC: modified Medical Research Council; NOVELTY: a NOVEL observational longiTudinal studY; PEF: peak expiratory flow; RSQ: Respiratory Symptoms Questionnaire; RTI: respiratory tract infection; SGRQ: St George's Respiratory Questionnaire. #: baseline and yearly data will be collected from healthcare professionals during clinical visits, while 3-monthly data will be collected directly from the patient via follow up by web-based platform or telephone, and in conjunction with their yearly clinical visits. ¶: the CAAT is a modified form of the validated COPD assessment test (CAT), which, with consent of the copyright holder (GlaxoSmithKline, Brentford, UK), excludes specific references to COPD in order to also assess patients without a COPD diagnosis; a small subset of patients with COPD will complete both the CAAT and CAT at baseline and year 1, to evaluate the equivalence of the two tests. +: only for patients with an asthma diagnosis, for comparison with the CAAT. §: for sites where spirometers are provided and data collected centrally, quality control/over-read and Best Test Review will be performed at baseline. ƒ: in Brazil, no samples will be collected; in China and Denmark, only samples for haematology will be collected; in Italy, no samples for DNA or RNA analysis will be collected; samples will be collected at each yearly visit in Australia, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden, the UK and the USA, and at year 1 only in other countries. ##: plasma will not be collected from adolescent patients.

      • TABLE 3

        Variables relating to the impact of disease, treatment and healthcare utilisation to be collected in NOVELTY

        VariableCollection#
        BaselineEvery 3 monthsYearly
        Physician-reportedPatient-reportedPatient-reportedPhysician-reportedPatient-reported
        Impact on daily activity and quality of life
         HRQoL
          SGRQ✓✓
          EQ-5D-5L✓✓✓
         WPAI✓✓
        Treatment(s) during previous 12 months
         Asthma/COPD treatments✓✓✓✓✓
         Treatment duration and frequency✓✓✓✓✓
         Posology✓✓
         Patterns of use and treatment adherence for asthma/COPD treatments✓✓✓✓
         Burden of out-of-pocket asthma/COPD treatment expenses¶✓✓
         Reasons for switching/ interruptions/discontinuations of each asthma or COPD treatment✓✓✓✓
         Asthma/COPD treatment satisfaction✓✓✓
         Concomitant medications✓✓
        Healthcare utilisation during previous 12 months (eCRF) or previous 3 months (PROs)
         Medications, emergency and nonemergency physician visits✓✓✓✓✓
         Respiratory and nonrespiratory hospitalisations✓✓✓✓✓
         Out-of-pocket expenses (USA only)✓✓
         Exacerbations, emergency department visits, hospitalisations, days in ICU✓✓✓✓✓
         Tests performed during exacerbations✓✓

        COPD: chronic obstructive pulmonary disease; eCRF: electronic case report form; EQ-5D-5L: EuroQol 5 dimensions 5 levels health questionnaire; HRQoL: health-related quality of life; ICU: intensive care unit; NOVELTY: a NOVEL observational longiTudinal studY; PRO: patient-reported outcome; SGRQ: St George's Respiratory Questionnaire; WPAI: work productivity and activity impairment. #: baseline and yearly data will be collected from healthcare professionals during clinical visits, while 3-monthly data will be collected directly from the patient via follow up by web-based platform or telephone, and in conjunction with their yearly clinical visits. ¶: patients will be asked to consider the burden of out-of-pocket expenses in the 12 months prior to visit.

        Supplementary Materials

        • Figures
        • Tables
        • Supplementary Material

          Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

          Supplementary material 00036-2018_supp

        PreviousNext
        Back to top
        Vol 5 Issue 1 Table of Contents
        ERJ Open Research: 5 (1)
        • Table of Contents
        • Index by author
        Email

        Thank you for your interest in spreading the word on European Respiratory Society .

        NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

        Enter multiple addresses on separate lines or separate them with commas.
        Prospective observational study in patients with obstructive lung disease: NOVELTY design
        (Your Name) has sent you a message from European Respiratory Society
        (Your Name) thought you would like to see the European Respiratory Society web site.
        CAPTCHA
        This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
        Print
        Citation Tools
        Prospective observational study in patients with obstructive lung disease: NOVELTY design
        Helen K. Reddel, Maria Gerhardsson de Verdier, Alvar Agustí, Gary Anderson, Richard Beasley, Elisabeth H. Bel, Christer Janson, Barry Make, Richard J. Martin, Ian Pavord, David Price, Christina Keen, Asparuh Gardev, Stephen Rennard, Alecka Sveréus, Aruna T. Bansal, Lance Brannman, Niklas Karlsson, Javier Nuevo, Fredrik Nyberg, Simon S. Young, Jørgen Vestbo
        ERJ Open Research Feb 2019, 5 (1) 00036-2018; DOI: 10.1183/23120541.00036-2018

        Citation Manager Formats

        • BibTeX
        • Bookends
        • EasyBib
        • EndNote (tagged)
        • EndNote 8 (xml)
        • Medlars
        • Mendeley
        • Papers
        • RefWorks Tagged
        • Ref Manager
        • RIS
        • Zotero
        Share
        Prospective observational study in patients with obstructive lung disease: NOVELTY design
        Helen K. Reddel, Maria Gerhardsson de Verdier, Alvar Agustí, Gary Anderson, Richard Beasley, Elisabeth H. Bel, Christer Janson, Barry Make, Richard J. Martin, Ian Pavord, David Price, Christina Keen, Asparuh Gardev, Stephen Rennard, Alecka Sveréus, Aruna T. Bansal, Lance Brannman, Niklas Karlsson, Javier Nuevo, Fredrik Nyberg, Simon S. Young, Jørgen Vestbo
        ERJ Open Research Feb 2019, 5 (1) 00036-2018; DOI: 10.1183/23120541.00036-2018
        del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
        Full Text (PDF)

        Jump To

        • Article
          • Abstract
          • Abstract
          • Introduction
          • Methods
          • Discussion
          • Supplementary material
          • Acknowledgements
          • Footnotes
          • References
        • Figures & Data
        • Info & Metrics
        • PDF

        Subjects

        • Asthma and allergy
        • COPD and smoking
        • Tweet Widget
        • Facebook Like
        • Google Plus One

        More in this TOC Section

        • Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy
        • Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from ICS/LABA therapy in patients with asthma: REACH study design
        • Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
        Show more Study protocol

        Related Articles

        Navigate

        • Home
        • Current issue
        • Archive

        About ERJ Open Research

        • Editorial board
        • Journal information
        • Press
        • Permissions and reprints
        • Advertising

        The European Respiratory Society

        • Society home
        • myERS
        • Privacy policy
        • Accessibility

        ERS publications

        • European Respiratory Journal
        • ERJ Open Research
        • European Respiratory Review
        • Breathe
        • ERS books online
        • ERS Bookshop

        Help

        • Feedback

        For authors

        • Instructions for authors
        • Publication ethics and malpractice
        • Submit a manuscript

        For readers

        • Alerts
        • Subjects
        • RSS

        Subscriptions

        • Accessing the ERS publications

        Contact us

        European Respiratory Society
        442 Glossop Road
        Sheffield S10 2PX
        United Kingdom
        Tel: +44 114 2672860
        Email: journals@ersnet.org

        ISSN

        Online ISSN: 2312-0541

        Copyright © 2023 by the European Respiratory Society